On September 19, 2014, Mary-Claire King received the 2014 Lasker-Koshland Special Achievement Award in Medical Science given for exceptional leadership and citizenship in biomedical science. Her citation read: "For bold, imaginative, and diverse contributions to medical science and human rightsshe discovered the BRCA1 gene locus that causes hereditary breast cancer and deployed DNA strategies that reunite missing persons or their remains with their families."* In these days of specialization and high technology in genomics, Mary-Claire's work and recognition are ample proof that what matters in science is asking the right questions and then choosing the tools to answer them and not the other way around. Her studies have changed our science. Consider that she did so in three different areas! Mary-Claire's scientific achievements are many, but her three cardinal accomplishments are her discovery of the BRCA1 gene locus, her (and her mentor Allan Wilson's) recognition of the importance of evolution in regulatory regions outside genes, and her applications of everyday genetic principles to solve human rights abuse cases (1) . In each of these areas, her work and imprint have been exemplary, characterized by simplicity and elegance. She is a remarkable character, full of wit, wisdom, and opinion, sometimes strongly held ones, and ample fodder for a movie: indeed no less an actress than Oscar-winning Helen Hunt has portrayed her in Decoding Annie Parker (2). It's difficult to do justice to her contributions and impact in a short profile, beyond what has already been written by others and her (1, 3) . What I will add rather are the contexts in which her discoveries were made and which highlight her scientific courage.
Breast cancer, long known to be a common disorder in human societies, has been particularly devastating to some families where many women succumb to this disease. This suffering has long been a part of human history, because the ancient Greek physicians knew of such families. However, its formal study can be traced to the late 19th century and Paul Broca, who was the first to precisely describe familial breast cancer (in his wife's family) and attribute the "latency" of its onset to heredity (4) . The idea of familial breast cancer has been neither unknown nor controversial: indeed, in the 1940s, the Danish geneticist Oluf Jacobsen collected ∼200 pedigrees to demonstrate the familial nature and features of breast cancer (5) . In the 1950s and 1960s, however, we witnessed numerous epidemiological investigations to identify suspected environmental risk factors, given the possibility of our interventions. At that time, genetic factors in complex disorders were considered neither important nor common. Nevertheless, the breast cancer data stubbornly showed, again and again, that a family, and personal, history of breast cancer was the most potent risk factor.
Mary-Claire's odyssey to understand breast cancer began with trying to quantify the degree and pattern of this excess familial risk. She was quite aware that the familiality of breast cancer could be explained by many genetic and environmental causes; however, she argued that "complex segregation analysis," a state-of-the-art quantitative genetics computing technology in the 1980s, could perhaps discriminate between some of these hypotheses. Based on a collection of 1,579 families collected through the National Cancer Institute, she did precisely that (6) . Other studies, based on Jacobsen's data, had also concluded the same (7). Mary-Claire's studies convincingly demonstrated that the excess risk was not shared by all but a small fraction (4%) of families who developed disease, owing to a rare but highly penetrant autosomal dominant susceptibility gene; this putative allele raised a bearer's breast cancer risk over their lifetime from 8% to 82% by age 70 (6) . As she has herself said, "The model was purely mathematical, and the gene was, of course, hypothetical" (3). This breast cancer hypothesis had two corrolaries: autosomal dominant inheritance in only some families, so that not all familial cases would harbor a mutant gene, and genetic heterogeneity, so that not all dominant looking families segregate mutations at the same gene. These possibilities made a gene hunt complicated, but they would remain mere possibilities unless one mapped the underlying gene(s). The chances of doing so successfully were slim indeed in the 1980s, despite the gaining popularity and success of positional cloning. To champion this scientific search and to keep to that task despite the unknown odds of success took courage and a great belief in the scientific importance of the question. Mary-Claire persisted and, in 1990, she and her team hit paydirt by demonstrating genetic linkage between breast cancer susceptibility and an anonymous Mary-Claire King.
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The author declares no conflict of interest. marker on human chromosome 17 (8) . They were astute to notice that the weak genetic linkage in all families grouped together arose from a mixture of linked and unlinked families depending on early (<45 years) or late age of cancer onset (8) . This result was not a forgone conclusion because the families could have been classified by many different features thought to be risk factors, none of which would have mattered but would have extracted a statistical price to claim significance: the larger the numbers of hypotheses tested, the greater the statistical significance demanded to ward off false positives. Success came here by invoking the genetic argument that the putative gene's penetrance increased over time and therefore time to onset was indeed the critical variable (6) .
This critical observation was indeed the impetus to many to consider positional cloning of "the breast cancer gene." This was not necessarily thought to be feasible because, until then, all such cloned genes were for Mendelian disorders. In fact, the scientific and personal stories of the identification of the BRCA1 gene as the etiological cause was neither easy nor simple, as she has herself described (3), but was one that we all followed with interest (3). Slowly, but surely, Mary-Claire's group mapped and narrowed the genomic location where the putative gene was located. Then, in October 1994, Mark Skolnick and his colleagues from the then new biotechnology company Myriad Genetics announced their identification of BRCA1 in five breast and ovarian cancer families (9) . This exciting discovery was elaborated on a few weeks later at the American Society of Human Genetics Annual Meeting in Montreal. Undaunted, at the same session, Mary-Claire presented new data showing segregation of BRCA1 mutations in 10 additional families (10) and received a spontaneous standing ovation from the crowd. We, the community, applauded her for many reasons: she was one of our own, she had been in our shoes, and we were elated that the genetic approach worked more broadly than for Mendelian diseases. We were also hoping that many more such genes would soon be discovered (11) .
There is no doubt that Myriad Genetics was the first to identify BRCA1; however, without Mary-Claire's discovery of the BRCA1 locus and without her doggedness and her intuition, gene identification would have taken much, much longer (1) . Today, such a search would be much easier given large-scale sequencing, and indeed, many oncogenes and tumor suppressor genes have been identified this way (11, 12) . More broadly, genes for many complex disorders are been sought and being discovered through sequencing. However, most of these studies are being conducted on patient collections without regard to many critical risk factors, particularly family history, which is A, if not THE, leading risk factor for the majority of complex disorders. The success of BRCA1 relied on understanding genetic risk, and this required the collection of families, carefully and diligently. It is a task that requires patience, luck, and a great belief in the scientific value of a few wellcollected pedigrees rather than sheer numbers; it is decidedly not high throughput. The Mary-Claire BRCA1 story is thus one of the success stories of the power of genetic logic: she used an exception to uncover the rule.
The pursuit of genetically exceptional patients, those at high risk of familial recurrence, is fruitful because they generally arise from highly deleterious coding mutations that we can recognize easily. This was clearly Mary-Claire's evolutionary raison d'etre for studying high-risk breast cancer families where highly deleterious should abound; indeed, BRCA1 harbors numerous protein-truncating mutations. Consequently, these mutations seldom survive evolution. This was a lesson she learned long ago, during her doctoral dissertation with Allan Wilson, a brilliant and inventive scientist and humanist, at the University of California, Berkeley, when the two set out to identify the expected protein polymorphisms and fixed differences between humans and chimps. This was in the 1970s when studying protein polymorphisms by starch gel electrophoresis was the new high-throughput technology. Finding little change, they concluded that these two species must have near identical (99%) genomes. They could have written a paper simply documenting these facts. Instead, they created a masterpiece. They claimed that because protein differences between humans and chimps were slight, and that their morphological and behavioral differences were quite substantial, evolution occurs at two different levels for anatomical traits and for macromolecules. They further argued that because many genetic mutations must have accumulated, and they failed to find many, such differences must exist outside genes and be regulatory (13) .
This regulatory hypothesis for evolution is a remarkable inference given the limited knowledge of the genome in 1975 and represents a kind of cool, daring, logical conclusion that Mary-Claire learned early and uses often. The duo went further and speculated: "Some of these changes may result from the rearrangement of genes on chromosomes rather than from point mutations." This specific hypothesis is yet to be proven but remains just as compelling today as it was in 1975. In the intervening years, there has been plenty of evidence for the predicted regulatory changes in evolution for specific traits from apical dominance in maize (14) to body armor in sticklebacks (15) . With sequencing of the human genome and studies of the meaning of noncoding DNA, we are at the dawn of trying to make sense of this regulatory apparatus and deciphering its precise functions (16) . Now we also know that some of these regulatory sequences are also compromised in human disease and became prominent through natural selection (17) . We are only now beginning to have this new view of genomes from a journey MaryClaire started us on a long time ago.
The third area in which Mary-Claire King has made a major impact is in the use of genetic markers to connect the remains of victims to their families. This is not discovery science, but deserves to be mentioned given its profound impact on humanity, because it is discovery nevertheless. Her work in this direction started in 1984 and came from her involvement in connecting the Abuelas de Plaza de Mayo (Grandmothers of Plaza de Mayo) in Argentina with their grandchildren. These were not any grandchildren, but children who were born to women in prison and then were abducted and illegally "adopted" by military families. These were not ordinary women but political dissidents who were jailed, persecuted, tortured, and later "disappeared" after being abducted by the military dictatorship during the Argentinian eightyear "Dirty War" (1, 18) . This was not an isolated gesture but a beginning to using genetics to solve numerous human rights abuse cases across the world. Its principles are simple enough that any lay person can understand and high school students can master, but their applications required constantly improving DNA-based identification technology. These efforts represent one of the most simple and yet most powerful applications of genetic principles based on the unique sharing of DNA between close relatives. Today, one of the greatest successes of genetics is that Americans, and increasingly others around the world, believe that DNA is the surest way to prove one's innocence when convicted of a crime.
There are few scientists who have had such a profound influence on the applications and practice of genetics in one the
